Light-chain amyloidosis: SCT, novel agents and beyond

Bone Marrow Transplantation

Volumn 48, Issue 8, 2013, Pages 1022-1027

  Rosenzweig, M ^a   Giralt, S ^b   Landau, H ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bortezomib; Immunotherapy; Light chain amyloidosis; Transplantation

Indexed keywords

ALKYLATING AGENT; AMYLOID; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FIBRILLAR PROTEIN; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; POMALIDOMIDE; PREDNISONE; PROTEIN; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOACCUMULATION; BIOPSY; CELL POPULATION; CONSOLIDATION CHEMOTHERAPY; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; ERADICATION THERAPY; HEART FAILURE; HUMAN; IMMUNOTHERAPY; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MORTALITY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SURVIVAL; SYSTEMIC DISEASE; TARGET CELL; THROMBOEMBOLISM; UREMIA;

AMYLOIDOSIS; ANIMALS; BORONIC ACIDS; DEXAMETHASONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MELPHALAN; PYRAZINES; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84881372477     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.199     Document Type: Review

References (82)

1. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 2010; 38: 97-106
2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909
3. Kyle RA, Bayrd ED. 'Primary' systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Arch Intern Med 1961; 107: 344-353
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59
5. Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992; 79: 1817-1822
6. Merlini G, Seldin DC, Gertz MA. Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933
7. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: A status report. Leuk Lymphoma 2010; 51: 2181-2187
8. Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: Patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107: 3489-3491
9. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen 3rd HR, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957-4959
10. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9: 108-114
11. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346: 1786-1791
12. Comenzo RL. How I treat amyloidosis. Blood 2009; 114: 3147-3157
13. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-Associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-246
14. Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010; 116: 1990-1991
15. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497
16. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study. Blood 2011; 118: 865-873
17. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86: 180-186
18. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-Terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757
19. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989-995
20. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-Terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica 2011; 96: 1079-1080
21. Girnius S, Seldin DC, Quillen K, Andrea NT, Sloan JM, Berk JL et al. High-dose melphalan and stem cell transplantation for patients with al amyloidosis and cardiac involvement. ASH Annual Meeting Abstracts 2011; 118: 2043
22. Wechalekar A, Schonland SO, Kastritis E, Hawkins PN, Dimopoulos MA, Russo P et al. European Collaborative Study of Treatment Outcomes in 347 patients with systemic AL amyloidosis with mayo stage III disease. ASH Annual Meeting Abstracts 2011; 118: 995
23. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007; 92: 1415-1418
24. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. Highdose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004; 140: 85-93
25. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19: 136-141
26. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328
27. Palladini G, Dispenzieri A, Gertz MAA, Wechalekar A, Hawkins PN, Schonland SO et al. Validation of the criteria of response to treatment in al amyloidosis. Blood 2010; 116: 586-587
28. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012
29. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207
30. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K et al. Doseintensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996; 88: 2801-2806
31. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998; 91: 3662-3670
32. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963-969
33. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104: 553-559
34. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853-855
35. Gillmore JDAJ, Craddock C et al. High Dose Melphalan and Stem Cell Rescue for Al Amyloidosis. Parthenon Publishing Pearl River: NY, 1999
36. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998; 101: 766-769
37. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276-4282
38. Syme R, Bewick M, Stewart D, Porter K, Chadderton T, Gluck S. The role of depletion of dimethyl sulfoxide before autografting: On hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004; 10: 135-141
39. Fois E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D et al. Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: Analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant 2007; 40: 831-835
40. Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 2009; 104: 990-994
41. Kumar S, Dispenzieri A, Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008; 358: 91-93
42. Gertz M, Lacy M, Dispenzieri A, Hayman S, Kumar S, Buadi F et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36-41
43. Refinement in Patient Selection Can Reduce the Treatment-Related Mortality from Stem Cell Transplantation in Amyloidosis to o2%. XIII International Symposium on Amyloidosis. (Groningen: The Netherlands, 2012
44. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Riskadapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: Results of a phase II trial. Br J Haematol 2007; 139: 224-233
45. Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-Term results in a series of 421 patients. Blood 2011; 118: 4346-4352
46. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005; 35: 567-575
47. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA et al. Riskadjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025-1031
48. Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD et al. Consolidation with bortezomib and dexamethasone following risk-Adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid-J Protein Folding Disord 2011; 18: 135-136
49. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-Adapted melphalan and stem cell transplantation for patients with newly diagnosed light chain amyloidosis. Leukemia 2013; 27: 823-828
50. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. Highdose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093
51. Jaccard A, Leblond V, Royer B, Leleu X, Delarue R, Kolb B et al. Autologous stem cell transplantation (asct) versus oral melphalan and high-dose dexamethasone in patients with al (primary) amyloidosis: Long term follow-up of the French Multicentric Randomized Trial. ASH Annual Meeting Abstracts 2010; 116: 1344
52. Gillmore JD, Davies J, Iqbal A, Madhoo S, Russell NH, Hawkins PN. Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998; 100: 226-228
53. Kawai Y, Kinoshita K, Arai H, Kuwata A. Fukuoka Y, Yamaoka M et al. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. Eur J Haematol 2004; 72: 448-450
54. Guillaume B, Straetmans N, Jadoul M, Cosyns JP, Ferrant A. Allogeneic bone marrow transplantation for AL amyloidosis. Bone Marrow Transplant 1997; 20: 907-908
55. Imamura T, Ogata M, Kohno K, Tomo T, Ohtsuka E, Kikuchi H et al. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis. Am J Hematol 2006; 81: 281-283
56. Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107: 2578-2584
57. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM et al. Lowdose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117: 886-889
58. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/ alpha interferon in patients with primary systemic amyloidosis: Results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520-3526
59. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938
60. Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L et al. Treatment with oral melphalan plus dexamethasone produces long-Term remissions in AL amyloidosis. Blood 2007; 110: 787-788
61. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257-261
62. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007; 109: 492-496
63. Hegenbart U, Bochtler T, Dietrich S, Ho AD, Schonland S. Treatment of light chain amyloidosis patients with lenalidomide and dexamethasone after failure of melphalan-containing chemotherapies. Amyloid-J Protein Folding Disord 2010; 17: 186-187
64. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 2008; 112: 1522-1528
65. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49: 1108-1115
66. Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: A multicenter phase 1/2 dose-escalation study. Blood 2010; 116: 4777-4782
67. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Longterm results from a phase 2 trial. Blood 2012; 119: 4860-4867
68. Dispenzieri A, Gertz MA, Hayman SR, Buadi F, Kumar SK, Reeder C et al. Pomalidomide and dexamethasone for previously treated AL: A phase 2 study. Amyloid-J Protein Folding Disord 2010; 17: 87-87
69. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010; 85: 757-759
70. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031-1037
71. Zonder JA, Sanchorawala V, Snyder RM, Matous J, Terebelo H, Janakiraman N et al. Melphalan and dexamethasone plus bortezomib induces hematologic and organ responses in al-Amyloidosis with tolerable neurotoxicity. Blood 2009; 114: 310-311
72. Zonder J, Sanchorawala V, Snyder R, Matous J, Terebelo H, Janakiraman N et al. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Amyloid-J Protein Folding Disord 2010; 17: 86-87
73. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394
74. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390
75. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010; 148: 760-767
76. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore Jr. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417: 254-259
77. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994; 91: 5602-5606
78. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-97
79. Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT et al. Antibodymediated resolution of light chain-Associated amyloid deposits. Am J Pathol 2000; 157: 1239-1246
80. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm 2003; 18: 853-860
81. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D et al. The cancer-Testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106: 167-174
82. Rosenzweig MA, Landau H, Seldin D, O'Hara C, Girnius S, Hanson N et al. Cancertestis antigen expression and immunogenicity in AL amyloidosis. Blood Cancer J 2012; 2: E90